https://pmc.ncbi.nlm.nih.gov/articles/PMC9699187/
Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma - PMC
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the...
combination therapyhodgkin lymphomanavitoclaxpromisingmimetic
https://adisinsight.springer.com/drugsafety/803850572?error=cookies_not_supported&code=00deabfa-bf28-462b-bc9b-9dc3bb2660cf
Navitoclax/Venetoclax - AdisInsight
In a retrospective, multicenter analysis, conducted between July 2019 and December 2022, two adult patients [sexes and exact ages not stated] were described,
navitoclaxvenetoclax
https://ecancer.org/en/video/9111-venetoclax-plus-navitoclax-in-r-r-all-and-lymphoblastic-lymphoma
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma - ecancer
Dr Elias Jabbour speaks to ecancer in an online interview for the virtual EHA 2020 meeting. He outlines the rationale behind this phase I dose-escalatio
venetoclaxplusnavitoclaxrlymphoma